Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer.

ABSTRACT:

Background

While tumor organoids hold promise for personalized medicine, clinical validation of epithelial ovarian cancer (EOC) organoids as predictors of therapeutic efficacy-particularly for PARP inhibitors (PARPi)-remains unestablished.

Methods

Patient-derived organoids (PDOs) were established from treatment-naive EOC specimens and characterized by H&E staining, immunohistochemistry, and whole-exome sequencing. Drug sensitivity testing (DST) was performed using carboplatin, paclitaxel, and PARPi (olaparib and niraparib). Clinical homologous recombination deficiency (HRD) status was assessed by tumor sequencing. Organoid responses were prospectively compared to patient outcomes after first-line chemotherapy (carboplatin/paclitaxel) and PARPi maintenance.

Results

PDO

SUBMITTER: Wang H 

PROVIDER: S-EPMC12797791 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature